Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil’s national health regulatory agency.

This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the company’s manufacturing facilities.

The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.